Replimune stock.

Replimune Group stock was originally listed at a price of $15.16 in Jul 20, 2018. If you had invested in Replimune Group stock at $15.16, your return over the last 5 years would have been 4.88%, for an annualized return of 0.96% (not including any dividends or dividend reinvestments).Get Replimune Group Inc (REPL.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsTo begin my analysis, Replimune's Q2 earnings revealed an upswing in expenditures, with R&D costs climbing 37% to $40.4M and SG&A expenses up 33% to $15.2M, culminating in a heightened operating ...Aug 14, 2023 · Replimune Group's results for treatment of patients with cutaneous squamous cell carcinoma are expected in Q4 2023. Click here to read our take on REPL stock. Replimune story: Exercise or conversion by Pamela Esposito of 25800 shares of Replimune subject to Rule 16b 3 and other headlines for Replimune Group

Track Replimune Group Inc (REPL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsThe Replimune Group Inc. stock price fell by -1.82% on the last day (Wednesday, 29th Nov 2023) from $11.53 to $11.32.During the last trading day the stock fluctuated 6.13% from a day low at $11.26 to a day high of $11.95.The price has been going up and down for this period, and there has been a 0.89% gain for the last 2 weeks.6 brokers have issued 12-month price objectives for Replimune Group's shares. Their REPL share price targets range from $34.00 to $70.00. On average, they anticipate the company's share price to reach $51.33 in the next year. This suggests a possible upside of 353.5% from the stock's current price.

WOBURN, Mass.Nov. 23, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic ...

10.39 +0.10 (0.97%) At close: Nov 24, 2023, 1:00 PM 10.86 +0.46 (4.48%) After-hours: Nov 24, 2023, 1:26 PM EST Financials No 1Y chart data available About …Nov 29, 2023 · The Replimune Group Inc. stock price fell by -1.34% on the last day (Wednesday, 22nd Nov 2023) from $10.43 to $10.29. During the last trading day the stock fluctuated 4.10% from a day low at $10.25 to a day high of $10.67. The price has fallen in 7 of the last 10 days and is down by -10.83% for this period. At Replimune, we are developing an emerging class of cancer treatments called oncolytic immunotherapies.­. Oncolytic immunotherapy has the potential to treat patients with a variety of tumor types and improve on existing immunotherapies. Our goal is to revolutionize cancer treatment by making personalized therapy a practical reality for all ...Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the ...Contact Email: [email protected]. Contact Phone Number: +1 (781) 222 9570. Replimune’s investigational products and their uses are investigational, have not been proven to be safe and have not been approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authority.

Oct 15, 2020 · Replimune (NASDAQ: REPL) stock price soared sharply to an all-time high of $46 in Wednesday trading before settling around $36 a share at the end of the session. The shares of the biotechnology company that develops oncolytic immune-gene therapies to treat cancer jumped 46% in Wednesday trading, accelerating twelve months gains to 196%.

Philip Astley-Sparke is a businessperson who founded Replimune Group, Inc. and who has been at the head of 6 different companies. He occupies the position of Chief Executive Officer & Director at Replimune Group, Inc. and Venture Partner at Forbion Capital Partners Management Holding BV. He previously held the position of Chairman at uniQure NV ...

Replimune’s tumor-directed oncolytic immunotherapies have the potential to redefine the cancer treatment paradigm. Replimune’s approach brings together multiple mechanisms of action to destroy the tumor, ignite an anti-cancer response, and generate long-lived immune activity. The ultimate aim is to improve outcomes for patients with cancer.Replimune Group Stock Performance. Shares of REPL stock opened at $11.71 on Monday. The company has a market cap of $691.58 million, a price-to-earnings ratio of -3.80 and a beta of 1.46. The stock has a 50 day simple moving average of $13.43 and a 200-day simple moving average of $18.08.When picking the best stocks under $10 to buy, it's important to identify fundamentally strong and non-speculative stocks. These are fundamentally strong and non-speculative stocks that are under $10 Since the meme stock euphoria in 2020, i...Replimune Group Inc REPL Morningstar Rating Stock XNAS Rating as of Nov 24, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns …Customizable interactive chart for Replimune Group Inc with latest real-time price quote, charts, latest news, technical analysis and opinions.Find the latest Replimune Group, Inc. (REPL) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears.

11.32. -0.21. -1.82%. WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio ...Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death …We would like to show you a description here but the site won’t allow us.Find the latest Replimune Group, Inc. (REPL) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears.18 Sep 2023 ... at Replimune and Gilead also shared how they're accelerating ... Veeva (VEEV stock) Exceptional Business! SaaS Growth Stock for Life Sciences ...

WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed ...

We conduct our clinical trials with the highest possible standards. Replimune is also closely monitoring the ongoing COVID-19 pandemic to ensure patient safety. To download and learn more detailed information about Oncolytic Immunotherapy and RP1, click here. You can find more information about our ongoing clinical trials below.Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.Altria stock (NYSE:MO) boasts a hefty 9.6% dividend yield, making its investment appeal stronger than ever. Despite ever-persistent concerns surrounding the tobacco industry and rising interest ...13 Jul 2023 ... Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the ...To begin my analysis, Replimune's Q2 earnings revealed an upswing in expenditures, with R&D costs climbing 37% to $40.4M and SG&A expenses up 33% to $15.2M, culminating in a heightened operating ...In other Replimune Group news, insider Pamela Esposito sold 5,358 shares of the business’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $20.01 ...

Dec 9, 2022 · In addition, Replimune has granted the underwriters a 30-day option to purchase up to an additional 1,436,172 shares of its common stock from Replimune at the public offering price, less the ...

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA. REPL - Replimune Group Inc - Stock screener for ...

14 Des 2022 ... in its approximately $260 million public offering of 6,810,658 shares of common stock, inclusive of the underwriters' option to purchase ...Track Replimune Group Inc (REPL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsNov 27, 2023 · November 29, 2023. $11.32. 786,621. 1:1. $11.67. $11.95. $11.26. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. Replimune Group, Inc. (REPL) stock forecast and price target. Find the latest Replimune Group, Inc. REPL analyst stock forecast, price target, and recommendation trends with in-depth analysis from ...Replimune Group, Inc. (REPL) has been beaten down lately with too much selling pressure. While the stock has lost 14.6% over the past four weeks, there is light at the end of the tunnel as it is ...Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added ... If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.Replimune's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Find out why REPL stock is a Buy.

Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Find out all the key statistics for Replimune Group, Inc. (REPL), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. ... Stock Price History ...PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …Instagram:https://instagram. how to earn money in forex tradingpublicly traded artificial intelligence companiesbest investment classesishares us real estate etf Stock USD 19.28 0.44 2.23% Given the investment horizon of 90 days and your slightly conservative level of risk, our recommendation regarding Replimune Group is 'Hold'Replimune Group Stock (NASDAQ: REPL) stock price, news, charts, stock research, profile. best strategy for forex tradingc3.ai stocks Replimune Group, Inc. ( NASDAQ:REPL – Get Free Report) shares were down 3.4% during trading on Friday . The company traded as low as $10.80 and last …REPL Replimune Group Inc Nov 24 • 01:26PM ET 10.85 +0.56 5.49% Healthcare • Biotechnology • USA • NASD Stock Detail • Compare Perf. • Options Chain … cxai stock news Replimune Group stock price forecast: $52; Market Cap: 686.26M, Enterprise value: 781.76M, P/E: -5.9, PEG ratio: 0.20, EPS: -3.1, Revenue: N/A, ...8 Des 2022 ... ... Replimune's asset could be the go-to product when anti-PD-1 therapy has failed. The stock closed up 22% yesterday, allowing the group to ...WOBURN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of …